Three patients living with hypertrophic cardiomyopathy have had their disease classification downgraded following a single ...

IgniteData has announced a partnership with AstraZeneca, MSK for launching the Archer tool for automation of EHR-to-EDC in a ...

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in ...

The therapeutic approach was safe, but the study did not meet its primary efficacy outcome using the six-minute walking test.

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III.

Results from the company’s trial of 3,500 patients found that disease burden was higher in men but women were at higher risk of MACE.

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were ...

According to GlobalData, out of the clinical trials with a 2024 start date, 41.4% of trials were ongoing, recruiting; 32.2% ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...

The Lancet research papers build on the WHO’s Guidance for best practices in clinical trials released in September 2024.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...